SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-423181"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-423181" > Comorbidities and c...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005670naa a2200661 4500
001oai:DiVA.org:uu-423181
003SwePub
008201021s2020 | |||||||||||000 ||eng|
009oai:DiVA.org:liu-170688
009oai:prod.swepub.kib.ki.se:144733375
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4231812 URI
0247 a https://doi.org/10.1016/j.ijcard.2020.04.0682 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1706882 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1447333752 URI
040 a (SwePub)uud (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Savarese, Gianluigiu Karolinska Institutet4 aut
2451 0a Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum :b A blueprint for clinical trial design
264 1b Elsevier BV,c 2020
338 a electronic2 rdacarrier
500 a Funding Agencies|Boehringer IngelheimBoehringer Ingelheim; EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@ Heart grant [116074]
520 a BackgroundComorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced (HFmrEF) vs. reduced (HFrEF) ejection fraction (EF), complicating trial design. In patients with HF, we performed a comprehensive analysis of type 2 diabetes (T2DM), atrial fibrillation (AF) chronic kidney disease (CKD), and cause-specific outcomes.Methods and resultsOf 42,583 patients from the Swedish HF registry (23% HFpEF, 21% HFmrEF, 56% HFrEF), 24% had T2DM, 51% CKD, 56% AF, and 8% all three comorbidities. HFpEF had higher prevalence of CKD and AF, HFmrEF had intermediate prevalence of AF, and prevalence of T2DM was similar across the EF spectrum. Patients with T2DM, AF and/or CKD were more likely to have also other comorbidities and more severe HF. Risk of cardiovascular (CV) events was highest in HFrEF vs. HFpEF and HFmrEF; non-CV risk was highest in HFpEF vs. HFmrEF vs. HFrEF. T2DM increased CV and non-CV events similarly but less so in HFpEF. CKD increased CV events somewhat more than non-CV events and less so in HFpEF. AF increased CV events considerably more than non-CV events and more so in HFpEF and HFmrEF.ConclusionHFpEF is distinguished from HFmrEF and HFrEF by more comorbidities, non-CV events, but lower effect of T2DM and CKD on events. CV events are most frequent in HFrEF. To enrich for CV vs. non-CV events, trialists should not exclude patients with lower EF, AF and/or CKD, who report higher CV risk.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Type 2 diabetes mellitus
653 a Chronic kidney disease
653 a Atrial fibrillation
653 a Heart failure
653 a Ejection fraction
653 a Trial design
7001 a Settergren, Camillau Karolinska Institutet4 aut
7001 a Schrage, Benediktu Karolinska Institutet4 aut
7001 a Thorvaldsen, Tonjeu Karolinska Institutet4 aut
7001 a Löfman, Idau Karolinska Inst, Div Cardiol, Dept Med, SE-17176 Stockholm, Sweden4 aut
7001 a Sartipy, Ulriku Karolinska Institutet4 aut
7001 a Mellbin, Lindau Karolinska Institutet4 aut
7001 a Meyers, Andreau Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA4 aut
7001 a Farsani, Soulmaz Fazeliu Boehringer Ingelheim Int GmbH, Ingelheim, Germany4 aut
7001 a Brueckmann, Martinau Boehringer Ingelheim Int GmbH, Ingelheim, Germany; Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany4 aut
7001 a Brodovicz, Kimberly G.u Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA4 aut
7001 a Vedin, Olau Uppsala universitet,Kardiologi,Boehringer Ingelheim AB, Stockholm, Sweden,Boehringer Ingelheim AB, Sweden; Uppsala Univ, Sweden4 aut0 (Swepub:uu)olved933
7001 a Asselbergs, Folkert W.u Univ Utrecht, Univ Med Ctr Utrecht, Div Heart & Lungs, Dept Cardiol, Utrecht, Netherlands; UCL, Fac Populat Hlth Sci, Inst Cardiovasc Sci, London, England; UCL, Hlth Data Res UK, London, England; UCL, Inst Hlth Informat, London, England4 aut
7001 a Dahlström, Ulfu Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US4 aut0 (Swepub:liu)ulfda85
7001 a Cosentino, Francescou Karolinska Institutet4 aut
7001 a Lund, Lars H.u Karolinska Institutet4 aut
7102 a Karolinska Institutetb Karolinska Inst, Div Cardiol, Dept Med, SE-17176 Stockholm, Sweden4 org
7730 t International Journal of Cardiologyd : Elsevier BVg 313, s. 76-82q 313<76-82x 0167-5273x 1874-1754
8564 u https://doi.org/10.1016/j.ijcard.2020.04.068y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1478112/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://www.internationaljournalofcardiology.com/article/S016752732031679X/pdf
8564 u https://liu.diva-portal.org/smash/get/diva2:1477677/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423181
8564 8u https://doi.org/10.1016/j.ijcard.2020.04.068
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170688
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144733375

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy